Case Reports in Gastroenterology最新文献_第7页

Life-Threatening Upper Gastrointestinal Bleeding following Percutaneous Endoscopic Gastrostomy Tube Removal under Traction: A Case Report. 经皮内镜胃造口管牵引下拔除后危及生命的上消化道出血1例报告。

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-12-04 eCollection Date: 2026-01-01 DOI: 10.1159/000548125

Christopher J Shephard, Xiaomin Ma, Rozemary Karamatic

{"title":"Life-Threatening Upper Gastrointestinal Bleeding following Percutaneous Endoscopic Gastrostomy Tube Removal under Traction: A Case Report.","authors":"Christopher J Shephard, Xiaomin Ma, Rozemary Karamatic","doi":"10.1159/000548125","DOIUrl":"10.1159/000548125","url":null,"abstract":"Introduction: Percutaneous endoscopic gastrostomy (PEG) tubes are commonly used to facilitate long-term enteral nutrition. Selected PEG tubes may be appropriately removed without endoscopic guidance via gentle traction, which is seldom associated with major bleeding sequelae. Rare reports of major upper gastrointestinal (GI) hemorrhage following PEG tube removal have been managed using Foley catheter balloon tamponade or endoscopic over-the-scope clipping. Prompt reinsertion of a PEG tube may also be considered.Case presentation: We present the case of a multi-morbid 73-year-old female who experienced life-threatening hemodynamically unstable upper GI bleeding following traction PEG tube removal, which proved refractory to standard endoscopic measures of adrenaline injection and hemostatic clipping, as well as rotational thromboelastometry-guided correction of consumptive coagulopathy. There was no suitable target for angioembolization. Ultimately, in the context of continued hemodynamically unstable GI bleeding, definitive surgical hemostasis - a mode of intervention not frequently reported for bleeding of this nature - was achieved during emergency laparotomy via complete excision of the PEG tract and wedge excision of the involved stomach wall.Conclusion: Life-threatening hemodynamically unstable GI bleeding rarely complicates traction PEG tube removal. In elderly patients with multiple comorbidities, PEG tract bleeding refractory to standard endotherapy and not targetable by angioembolization can be safely and effectively managed with timely surgical intervention.","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"20 1","pages":"16-22"},"PeriodicalIF":0.6,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12810975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145997379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colonic Mucosal Pseudolipomatosis with Hemorrhage: A Case Report of Peracetic Acid-Induced Pathogenesis. 结肠粘膜假性脂肪瘤合并出血：过氧乙酸致发病1例。

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-24 eCollection Date: 2025-01-01 DOI: 10.1159/000548927

Chunxia Wang, Yu Zhong, Rihua Zheng

引用次数: 0

Iatrogenic Intramural Esophageal Dissection in Eosinophilic Esophagitis: A Rare Complication of Diagnostic Endoscopy in a Young Atopic Patient - Case Report and Review. 嗜酸性粒细胞性食管炎的医源性壁内食管夹层：一种罕见的年轻特应性患者内镜诊断并发症-病例报告与回顾。

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-21 eCollection Date: 2025-01-01 DOI: 10.1159/000548860

Thaer Swaid, Layth Hamzeh, Maryam Al Ahmad, Sulaman Magdub, Ishtiaq Ahmed

引用次数: 0

High-Dose Upadacitinib Maintenance Therapy for Refractory Crohn's Disease: A Case Series and Review of the Literature. 高剂量Upadacitinib维持治疗难治性克罗恩病：病例系列和文献综述

IF 0.7

Case Reports in Gastroenterology Pub Date : 2025-11-20 eCollection Date: 2026-01-01 DOI: 10.1159/000549674

Yousef Alfadhli, Reem Kermani, Mohammad Shehab

{"title":"High-Dose Upadacitinib Maintenance Therapy for Refractory Crohn's Disease: A Case Series and Review of the Literature.","authors":"Yousef Alfadhli, Reem Kermani, Mohammad Shehab","doi":"10.1159/000549674","DOIUrl":"10.1159/000549674","url":null,"abstract":"Introduction: Crohn's disease (CD) is a chronic, relapsing-remitting disorder affecting the gastrointestinal tract that falls under the umbrella term of inflammatory bowel disease (IBD). Its etiology is unknown, but it is suggested that there is a strong genetic and environmental interaction, leading to its development. The mainstay of treatment for patients with moderate to severe CD is advanced therapy, such as biologics or small molecules. Despite the use of these medications, the disease may be unresponsive to these agents, leading to refractory disease. The use of novel therapies expanded the treatment options for patients with refractory CD or those who failed multiple biologics. Upadacitinib (UPA), a small molecule drug, belongs to a class of medications known as Janus kinase (JAK) inhibitors. UPA is known to be effective against CD with a dosage of either 15 or 30 mg. However, this dose deemed to be ineffective in the cases we reported. A higher maintenance dose of 45 mg was introduced and the patient's reported resolution of symptoms. It is important to note that larger studies are required to prove the efficacy of this treatment for CD.Case presentations: This is a case-series of 3 patients with a history of refractory CD and prior exposure to at least 1 biologic agent, who achieved clinical remission and endoscopic healing on UPA maintenance therapy 45 mg orally once daily.Conclusion: This case series illustrates potential benefit and supports the rationale for larger controlled studies evaluating high-dose UPA maintenance therapy.","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"20 1","pages":"1-7"},"PeriodicalIF":0.7,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12721722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145818113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Treatment with Tezepelumab for an Adult with Refractory and Severe Fibrostenotic Eosinophilia Esophagitis: A Case Report. Tezepelumab成功治疗难治性重度纤维狭窄性嗜酸性粒细胞性食管炎1例。

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-19 eCollection Date: 2025-01-01 DOI: 10.1159/000549673

Joseph L Maniaci, Allison J Burbank, Evan S Dellon

{"title":"Successful Treatment with Tezepelumab for an Adult with Refractory and Severe Fibrostenotic Eosinophilia Esophagitis: A Case Report.","authors":"Joseph L Maniaci, Allison J Burbank, Evan S Dellon","doi":"10.1159/000549673","DOIUrl":"10.1159/000549673","url":null,"abstract":"Introduction: Non-response to treatment in eosinophilic esophagitis (EoE) is common, and the approach to treatment-refractory patients with EoE is challenging. With increasing knowledge of EoE pathogenesis, mechanisms can be targeted by medications that are approved for other atopic diseases with a similar pathophysiology.Case presentation: We present an adult with EoE who had longstanding symptoms prior to diagnosis, developed severe fibrostenosis with the narrow caliber phenotype requiring multiple esophageal dilations, and was previously nonresponsive to proton pump inhibitors (PPIs), topical corticosteroids (tCS), and food elimination diets (FED). Because of his concomitant severe asthma, he was treated with the eosinophil-depleting biologics mepolizumab and benralizumab. These reduced eosinophil counts on esophageal biopsy but did not improve symptoms, endoscopic features, or other histologic findings. He continued to require esophageal dilation for symptom control. His asthma control also remained suboptimal, prompting a trial of tezepelumab, an antibody against thymic stromal lymphopoietin (TSLP). In addition to controlling asthma, he improved across EoE symptom, endoscopic, and histologic metrics over a year of follow-up, including improvements in the EoE Endoscopic Reference Score, esophageal caliber, basal zone hyperplasia, dilated intercellular spaces, and lamina propria fibrosis as measured by the EoE Histologic Scoring System.Conclusion: This patient, who did not respond to PPI, FED, tCS, mepolizumab, or benralizumab, ultimately had response to tezepelumab across multiple outcome domains of EoE. This demonstrates proof-of-concept that targeting TSLP may be a promising modality in EoE and supports further study of this mechanism for treatment of EoE.","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"19 1","pages":"784-793"},"PeriodicalIF":0.6,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12707971/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145773626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inflammatory Bowel-Like Disease with Ileocolic and Perianal Involvement Induced by Ocrelizumab: A Case Report. 奥克雷单抗致炎性肠样疾病伴回结肠和肛周受累1例

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-18 eCollection Date: 2025-01-01 DOI: 10.1159/000549472

Caroline Soares, Ana Canastra, Ângela Domingues, Ana Catarina Carvalho, Diana Martins, Paula Sousa, Eugénia Cancela, Américo Silva, Paula Ministro

{"title":"Inflammatory Bowel-Like Disease with Ileocolic and Perianal Involvement Induced by Ocrelizumab: A Case Report.","authors":"Caroline Soares, Ana Canastra, Ângela Domingues, Ana Catarina Carvalho, Diana Martins, Paula Sousa, Eugénia Cancela, Américo Silva, Paula Ministro","doi":"10.1159/000549472","DOIUrl":"10.1159/000549472","url":null,"abstract":"Introduction: Immune-mediated colitis (IMC) is a common immune-related adverse event associated with immune checkpoint inhibitors. Other classes of biological therapy, such as monoclonal antibody with anti-CD20 activity, have also been associated with drug-induced gastrointestinal injuries, although through different immunomechanisms. In the literature, there are some previously described cases reporting on enterocolitis induced by rituximab and ocrelizumab highlighting its potential severity. Consequently, recently, the FDA amended the Prescribing Information of ocrelizumab to include IMC in the Warnings and Precautions section.Case presentation: We present the case of a patient with chronic diarrhea due to immune-mediated enterocolitis, markedly resembling Crohn's disease with ileocolic and perianal involvement induced by ocrelizumab. Endoscopically, this condition is indistinguishable from inflammatory bowel disease with significant overlap in histology. With discontinuation of ocrelizumab, the lesions and the symptoms disappeared. To our knowledge, this is the first case reporting perianal involvement.Conclusion: There are no clear recommendations on how to manage these patients. Clinicians must be aware of this entity and report on these unquestionably increasing conditions.","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"19 1","pages":"754-760"},"PeriodicalIF":0.6,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12695118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145741272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Duodenal Perforation following Argon Plasma Coagulation for Angiodysplasia: A Case Report. 氩等离子凝血治疗血管发育不良致十二指肠穿孔1例。

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-13 eCollection Date: 2025-01-01 DOI: 10.1159/000548871

Wei-Yu Chan, Kian-Hwee Chong, Chia-Chi Wang, Jiann-Hwa Chen, Tsung-Hsien Hsiao, Hung-Da Chen, Wei-Chih Su

引用次数: 0

Multiorgan Dysfunction in Severe Acute Pancreatitis: A Case of Septic Shock, Renal Cortical Necrosis, and Takotsubo Cardiomyopathy. 重症急性胰腺炎的多器官功能障碍：感染性休克、肾皮质坏死和Takotsubo心肌病1例。

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-12 eCollection Date: 2025-01-01 DOI: 10.1159/000548734

Bhavin Patel, Rachana Patel, Nisarg Hajariwala, Divya Sharma, Yogesh Bhargava, Parag Rana

引用次数: 0

A Simple Method for Removing Recyclable Metal Stents via Endoscopy: A Case Report. 内窥镜下取出可回收金属支架的简单方法1例。

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-12 eCollection Date: 2025-01-01 DOI: 10.1159/000549296

Yanfeng Xie, Pengfei Wang, Jin Jin, Wenbo Wang

{"title":"A Simple Method for Removing Recyclable Metal Stents via Endoscopy: A Case Report.","authors":"Yanfeng Xie, Pengfei Wang, Jin Jin, Wenbo Wang","doi":"10.1159/000549296","DOIUrl":"10.1159/000549296","url":null,"abstract":"Introduction: Gastrointestinal tract stenosis is a common pathological condition encountered in clinical practice, caused by various factors such as malignant tumors, postoperative anastomotic strictures, radiation injury, or inflammatory diseases like Crohn's disease. It often leads to serious complications, including dysphagia, obstruction, and malnutrition. Endoscopic metal stent placement has become a key treatment for alleviating both benign and malignant stenosis due to its minimally invasive nature, effectiveness, and repeatability. However, stent displacement is one of the most frequent complications, and its management requires a comprehensive approach based on the type of displacement (partial or complete), clinical symptoms, and anatomical location. Endoscopy is the preferred intervention method, and multidisciplinary collaboration can optimize patient outcomes.Case presentation: A 22-year-old male patient developed persistent nausea and vomiting 2 months ago after accidentally ingesting toilet cleaner. Gastroscopy revealed pyloric obstruction. After admission, a covered intestinal metal stent was placed. Two days later, the stent had migrated distally beyond the narrowed intestinal lumen. We attempted to directly remove the displaced stent under endoscopic visualization. However, the procedure was unsuccessful. Subsequently, we safely removed recyclable metal stents directly using a simple method: a transparent cap-fitted endoscope inserted through the forceps channel to control the stent's retrieval line.Conclusion: Our method of controlling the retrieval thread of the metal stent through endoscopic forceps to remove the displaced stent is feasible, safe, and effective.","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"19 1","pages":"746-753"},"PeriodicalIF":0.6,"publicationDate":"2025-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12685353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New-Onset Ulcerative Colitis after Secukinumab Initiation: A Case Report. Secukinumab启动后新发溃疡性结肠炎1例报告

IF 0.6

Case Reports in Gastroenterology Pub Date : 2025-11-11 eCollection Date: 2025-01-01 DOI: 10.1159/000548953

Hamila Hagh-Doust, Huzaifa Nadeem, Talat Bessissow, Peter L Lakatos

{"title":"New-Onset Ulcerative Colitis after Secukinumab Initiation: A Case Report.","authors":"Hamila Hagh-Doust, Huzaifa Nadeem, Talat Bessissow, Peter L Lakatos","doi":"10.1159/000548953","DOIUrl":"10.1159/000548953","url":null,"abstract":"Introduction: Secukinumab is an anti-interleukin (IL)-17 used in the treatment of rheumatological conditions such as ankylosing spondylitis and psoriasis. Despite elevated IL-17A levels in inflammatory bowel disease (IBD) patients, clinical trials suggest IL-17 inhibition may exacerbate disease activity in IBD. Multiple sclerosis (MS) also has a suspected association with IBDs.Case presentation: A 22-year-old man who has a paternal grandfather with a history of MS was started on secukinumab for suspected ankylosing spondylitis. Three months after secukinumab initiation, he developed new gastrointestinal (GI) symptoms and was diagnosed with ulcerative colitis. He responded to a course of corticosteroids, and his secukinumab was stopped. He remains in clinical and endoscopic remission 5 months after completing his course of steroids.Conclusions: This case highlights the potential association between IL-17 inhibition and new-onset IBD in a patient with a family history of MS and illustrates a compelling clinical dilemma regarding the initial selection of biologic therapy in a patient with multiple autoimmune risk factors. Before starting an anti-IL-17 agent, physicians should review the patient's personal and family history of IBD, as well as other risk factors, including immune-mediated conditions such as MS that may increase IBD risk. Patients should then be closely monitored for the development of any new GI symptoms.","PeriodicalId":9614,"journal":{"name":"Case Reports in Gastroenterology","volume":"19 1","pages":"726-730"},"PeriodicalIF":0.6,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12659643/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0